TY  - BOOK
AU  - Shereef Ahmed Elsammany
AU  - Mona Ali Sakr , 
AU  - Mostafa Mahmoud Elserafy , 
AU  - Sameh Sayed Ahmed Shamaa , 
TI  - Phase II study of low dose fixed rate infusion of gemcitabine with cisplatin and dexamethazone in resistant non- hodgkin lymphoma and correlation with MDR and BCL -2 expression / 
PY  - 2010///
CY  - Cairo : 
PB  - Shereef Ahmed Elsammany , 
KW  - Fixed rate
KW  - Gemcitabine
KW  - N.H.L
N1  - Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical; Issued also as CD
N2  - Despite significant advances in the managment of patients with aggressive non - hodgkin's lymphomas (NHLs) significant proportion of patients still experience relapse following initial response to therapy or even not responding to chemotherapy from the start . So there is a great priority for the development of new chemotherapy regimens in addition to new prognostic factors for respone and survival in patients with resistant disease
ER  -